RxDoctor Payments Data

Javier Hiriart, MD

Internal Medicine · Miami, FLNPI 1811929615

Payments from drug & device makers

$2,007in general payments, 2019–2025

Across 79 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$423
  • GSK$203
  • Dexcom, Inc.$177
  • Astellas Pharma US Inc$162
  • Pfizer$157
  • Exact Sciences$149
  • plus $737 from 16 others

What the payments were for

  • Food & beverage$1,92796%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,007 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$34,455
Medicare patients
129
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$61,033
OzempicSemaglutide60$58,838
EliquisApixaban37$43,162
ProliaDenosumab13$21,543
MounjaroTirzepatide16$16,816
SymbicortBudesonide/Formoterol Fumarate18$5,963
Atorvastatin Calcium274$2,695
Omeprazole139$2,627
Famotidine90$2,094
Rosuvastatin Calcium161$1,927
Levothyroxine Sodium130$1,864
Fluticasone Propionate89$1,738
Ezetimibe33$1,555
Losartan Potassium109$1,192
SynthroidLevothyroxine Sodium12$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$423$58,83860 claims
PfizerEliquis$157$43,16237 claims
AmgenProlia$40$21,54313 claims
Lilly USA, LLCMounjaro$79$16,81616 claims
AstraZenecaSymbicort$17$5,96318 claims
AbbVieSynthroid$14$1,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →